BLA 761051 · Kyowa Kirin
Poteligeo
Mogamulizumab-Kpkc · Injection · Chemokine Receptor Type 4 Interaction; Monoclonal Antibody
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Feb 19, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Aug 8, 2018
Approved uses
1
Original approval plus efficacy supplements
Registered trials
36
2 Phase 3, 8 recruiting
FAERS reports
1,361
819 serious, 198 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 2, 2026.
POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. POTELIGEO is a CC chemokine receptor type 4 (CCR4)-directed monoclonal antibody indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy ( 1 ).
Mechanism: Mogamulizumab-kpkc is a defucosylated, humanized IgG1 kappa monoclonal antibody that binds to CCR4, a G protein-coupled receptor for CC chemokines that is involved in the trafficking of lymphocytes to various organs. Non-clinical in vitro studies demonstrate mogamulizumab-kpkc binding targets a cell for antibody-dependent cellular cytotoxicity (ADCC) resulting in depletion of the target cells. CCR4 is expressed on the surface of some T-cell malignancies and is expressed on regulatory T-cells (Treg) and a subset of Th2 T-cells.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 8, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
1 products under this application
- POTELIGEO · MOGAMULIZUMAB-KPKC 20MG/5ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Mogamulizumab" as an intervention, any sponsor and status, largest first.
- A Study of VG712 in Patients With Mycosis FungoidesPivotal-lookingNot yet recruiting
Virogen Biotechnology Inc.Industry
NCT07529405 · 386 participants (planned) · Start Jul 30, 2026 · Primary completion Dec 30, 2030
Drug: VG712; Mogamulizumab · For: Mycosis Fungoides
Sites: Tampa, Florida
- Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCLPivotal-lookingCompleted
Kyowa Kirin, Inc.Industry
NCT01728805 · 372 participants · Start Nov 2012 · Primary completion Mar 2017
Drug: KW-0761; Vorinostat · For: Cutaneous T-Cell Lymphoma
Sites: Birmingham, Alabama; Gilbert, Arizona; Duarte, California · 73 sites in all
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
NCT06698003 · 134 participants (planned) · Start Nov 15, 2024 · Primary completion Nov 15, 2029
Drug: Mogamulizumab · For: T-Cell Leukemia/Lymphoma, Adult; T-cell Leukemia/Lymphoma; T-cell Leukemia and 1 more
Sites: Basking Ridge, New Jersey; Middletown, New Jersey; Montvale, New Jersey · 7 sites in all
Kyowa Kirin Co., Ltd.Industry
NCT02476123 · 118 participants · Start Jun 2015 · Primary completion Feb 7, 2018
Drug: Mogamulizumab: KW-0761, Nivolumab: (ONO-4538/BMS-936558) · For: Solid Tumor
Sites: Chiba, Japan; Tokyo, Japan
- Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid TumorsCompleted
Kyowa Kirin, Inc.Industry
NCT02705105 · 114 participants · Start Feb 2016 · Primary completion Aug 22, 2018
Drug: Mogamulizumab + Nivolumab · For: Solid Tumor; Cancer; Carcinoma and 2 more
Sites: Gilbert, Arizona; Greenbrae, California; Los Angeles, California · 15 sites in all
Kyowa Kirin, Inc.Industry
NCT01626664 · 71 participants · Start Jun 2012 · Primary completion Aug 2015
Drug: KW-0761; Pralatrexate and 2 more · For: Adult T-cell Leukemia-Lymphoma
Sites: Los Angeles, California; Miami, Florida; Chicago, Illinois · 20 sites in all
- A Study of KW-0761 in Subjects With HTLV-1 Associated Myelopathy (HAM)Pivotal-lookingTerminated
Kyowa Kirin Co., Ltd.Industry
NCT03191526 · 66 participants · Start May 22, 2017 · Primary completion Jun 6, 2019
Drug: KW-0761 0.3 mg/kg IV; Placebo (saline) · For: HTLV-1 Associated Myelopathy
Sites: Nagoya, Japan; Tone, Japan; Fukuoka, Japan · 16 sites in all
Kyowa Kirin, Inc.Industry
NCT02301130 · 64 participants · Start Nov 26, 2014 · Primary completion Dec 8, 2017
Drug: mogamulizumab; MEDI4736 (Durvalumab) and 1 more · For: Advanced Solid Tumors
Sites: Los Angeles, California; New Haven, Connecticut; Tampa, Florida · 7 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- rash193
- disease progression123
- drug eruption81
- pruritus68
- infusion related reaction59
- death55
- pyrexia52
- fatigue49
- inappropriate schedule of product administration42
- chills41
- drug ineffective37
- erythema36
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 3 |
| 2018 | 22 |
| 2019 | 210 |
| 2020 | 179 |
| 2021 | 223 |
| 2022 | 227 |
| 2023 | 109 |
| 2024 | 134 |
| 2025 | 125 |
| 2026 | 120 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Poteligeo (Mogamulizumab-Kpkc)
2024 spending
$1.8M
Beneficiaries
12
41 claims
Per beneficiary
$153,518
$914.25 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $629,052 |
| 2021 | $1,449,396 |
| 2022 | $1,261,538 |
| 2023 | $1,906,447 |
| 2024 | $1,842,214 |
Part B: Poteligeo (Mogamulizumab-Kpkc) · HCPCS J9204
2024 spending
$76.3M
Beneficiaries
344
3,771 claims
Per beneficiary
$221,874
2024 ASP limit $236.43 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $42,735,536 |
| 2021 | $52,270,180 |
| 2022 | $60,408,204 |
| 2023 | $62,069,663 |
| 2024 | $76,324,768 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Kim YH, Bagot M, Pinter-Brown L, et al. · Lancet Oncol 2018 · Clinical Trial, Phase III, Comparative Study
- Chemotherapy for non-Hodgkin lymphoma in the hemodialysis patient: A comprehensive review.
Yasuda H, Yasuda M, Komatsu N · Cancer Sci 2021 · Systematic Review
- A phase 2 trial of CHOP with anti-CCR4 antibody mogamulizumab for older patients with adult T-cell leukemia/lymphoma.
Yoshimitsu M, Choi I, Kusumoto S, et al. · Blood 2025 · Clinical Trial, Phase II, Multicenter Study
- An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma.
Izutsu K, Makita S, Nosaka K, et al. · Blood 2023 · Multicenter Study, Clinical Trial, Phase II
- Interventions for mycosis fungoides.
Valipour A, Jäger M, Wu P, et al. · Cochrane Database Syst Rev 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Mogamulizumab (Anti-CCR4) in HTLV-1-Associated Myelopathy.
Sato T, Coler-Reilly ALG, Yagishita N, et al. · N Engl J Med 2018 · Clinical Trial, Phase I, Clinical Trial, Phase II
Sponsor: Kyowa Kirin
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.